Healthcare deals I’d like to see in 2016: IBM buys athenahealth, Verizon buys a hospital and Kaiser Permanente buys a wine app
Go big or go home, healthcare. 2016 is the year to make big things happen.
Go big or go home, healthcare. 2016 is the year to make big things happen.
Also, more insight on the future of Theranos and pricing data from patients on video consults.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Also, new details about consumer attitudes toward healthcare and a Japanese ad agency invests in health trackers.
Who would've realized this was just the beginning?
On the road to pursue his next endeavor, Manny Villafana shared about why after decades in the medical device industry, he's still at it.
Also, Martin Shkreli is fired, mixed messages on a digital health survey, and nurses remain America's most trusted people.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Also, Novartis outlines a new future in drug pricing and get a deep drive into both Google Capital and GE Healthcare.
A lot of schadenfreude there.
For people who hate Shkreli for what he's done in 2015, this will be like the government getting Al Capone for tax evasion.
Also, a new deal for Illumina, a cure for Martin Shkreli, a controversial hospital acquisition and another Obamacare deadline approaches.
Also, bad news for Atara Biotherapeutics and an impressive local at healthcare startups that could help battle food poisoning.
A lengthy takeout in the Wall Street Journal with a passive-aggressive headline is never a good sign.
Also, new products from Modernizing Medicine, the end of Laguna Pharmaceuticals and a look at the implementation of the JOBS Act.
Also, Roche backs out of a superbug project, a look at text messaging in mental health, and a new Takeda-Teva partnership.
How can the new big medical investor make a big difference?